Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.63 |
| ▸ | MC3R | P41968 | 3/20 | 0.62 |
| ▸ | MC1R | Q01726 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MC5R | P33032 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470087 | 0.91 | MC4R (0.64) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3149279 | 0.91 | MC4R (0.64) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3154574 | 0.91 | MC4R (0.64) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3149271 | 0.91 | MC4R (0.64) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3156550 | 0.91 | MC4R (0.64) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3145173 | 0.91 | MC4R (0.69) | MC4RMC3RMC1RALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5464622 | 0.91 | MC4R (0.63) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3160946 | 0.90 | MC4R (0.64) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3148278 | 0.89 | MC4R (0.68) | MC4RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL3157837 | 0.88 | MC4R (0.60) | MC4RMC3RMC1RALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773796-B1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-03-03 | — | — | EP | claimed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | claimed |
| EP-1773796-B1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-03-03 | — | — | EP | disclosed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | MC5R, MC4R, OPRD1 | MC4R 2/4885MC3R 8/4885MC1R 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.